hydroxyurea has been researched along with Dysmyelopoietic Syndromes in 46 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC-GIMEMA 3 + 10 induction regimen (idarubicin + cytosine arabinoside) in adults with untreated acute myelogenous leukemia or high-risk myelodysplastic syndrome." | 9.19 | Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p ( Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R, 2014) |
| "An elderly woman receiving chronic hydroxyurea therapy for myelodysplasia developed a dermatomyositis-like eruption that was misdiagnosed as true dermatomyositis, leading to continuation of hydroxyurea." | 7.76 | Hydroxyurea-associated dermatomyositis-like eruption demonstrating abnormal epidermal p53 expression: a potential premalignant manifestation of chronic hydroxyurea and UV radiation exposure. ( Burruss, JB; Callen, JP; Cely, SJ; Kalajian, AH; Malone, JC, 2010) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 7.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| "Elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) have a poor prognosis due to low response rates (26-46%) to standard chemotherapy and high treatment-related mortality (11-31%)." | 6.73 | Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. ( Alkan, S; Barton, K; Germano, E; Godwin, J; Michaelis, L; Nand, S; Rychlik, K; Smith, S; Stiff, P; Veerappan, R, 2008) |
| "This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC-GIMEMA 3 + 10 induction regimen (idarubicin + cytosine arabinoside) in adults with untreated acute myelogenous leukemia or high-risk myelodysplastic syndrome." | 5.19 | Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p ( Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R, 2014) |
| "We have previously demonstrated that hydroxyurea (HU) reduces the rate of vascular complications in patients with essential thrombocythaemia (ET) at high risk of thrombosis." | 5.09 | Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. ( Barbui, T; Finazzi, G; Rodeghiero, F; Ruggeri, M, 2000) |
| "A 62-year-old man with refractory leukemia transformed from myelodysplastic syndrome was placed on hydroxyurea (hydroxycarbamide) at a daily dose of 500 mg." | 4.90 | [Hydroxyurea (hydroxycarbamide)-induced hepatic dysfunction confirmed by drug-induced lymphocyte stimulation test]. ( Karigane, D; Kikuchi, T; Koda, Y; Mori, T; Nakajima, H; Okamoto, S; Shimizu, T; Toyama, T, 2014) |
| "An elderly woman receiving chronic hydroxyurea therapy for myelodysplasia developed a dermatomyositis-like eruption that was misdiagnosed as true dermatomyositis, leading to continuation of hydroxyurea." | 3.76 | Hydroxyurea-associated dermatomyositis-like eruption demonstrating abnormal epidermal p53 expression: a potential premalignant manifestation of chronic hydroxyurea and UV radiation exposure. ( Burruss, JB; Callen, JP; Cely, SJ; Kalajian, AH; Malone, JC, 2010) |
| " In this study, we utilized these synergistic effects of granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim [Leukine]), hydroxyurea, and low-dose cytosine arabinoside to treat elderly patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS)." | 3.73 | GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS. ( Chan, GW; Miller, KB; Winer, ES, 2005) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 3.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| "Elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) have a poor prognosis due to low response rates (26-46%) to standard chemotherapy and high treatment-related mortality (11-31%)." | 2.73 | Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. ( Alkan, S; Barton, K; Germano, E; Godwin, J; Michaelis, L; Nand, S; Rychlik, K; Smith, S; Stiff, P; Veerappan, R, 2008) |
| "One of the MPDs, chronic myeloid leukemia (CML), has the distinct cytogenetic abnormality of the Philadelphia chromosome." | 2.42 | Treatment paradigms in the management of myeloproliferative disorders. ( Fruchtman, SM, 2004) |
| "Myelodysplastic syndrome with chromosomal translocation t(5;12)(q31-33;p12-13) and eosinophilia is a new entity recently described." | 2.39 | Myelodysplastic syndrome with t(5;12)(q31;p12-p13) and eosinophilia: a pediatric case with review of literature. ( Baranger, L; Blanchet, O; François, S; Ifrah, N; Larget-Piet, L; Le Moine, PJ; Pellier, I; Rialland, X, 1996) |
| "Hydroxyurea (HU) is a guideline-recommended cytoreductive therapy for patients at high risk for MPNs." | 1.91 | Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. ( Gore, SD; Huntington, SF; Ma, X; Podoltsev, NA; Shallis, RM; Stempel, JM; Wang, R; Zeidan, AM, 2023) |
| "Acute myeloid leukemia was finally diagnosed in October 1998, and chromosomal analysis disclosed inv(3) in addition to -5 and -7." | 1.31 | [Essential thrombocythemia in transformation from myelodysplastic syndrome to acute myeloid leukemia with inv(3) after treatment for gastric cancer]. ( Aoki, K; Chiba, S; Hirai, H; Honda, H; Horikoshi, M; Itikawa, M; Kurokawa, M; Machida, U; Masuda, S; Mitani, K; Ogawa, S; Seo, S; Sunaga, S; Yazaki, Y, 2000) |
| "We report a patient with Philadelphia chromosome positive (Ph +ve) chronic myelogenous leukemia (CML), treated with hydroxyurea alone, who upon disease progression developed an additional Ph - ve clone containing chromosomal abnormalities typical of myelodysplastic syndrome (MDS)." | 1.31 | Coexistence of independent myelodysplastic and Philadelphia chromosome positive clones in a patient treated with hydroxyurea. ( Flamm, MJ; Murty, VV; Nichols, GL; Rao, PH, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.17) | 18.7374 |
| 1990's | 9 (19.57) | 18.2507 |
| 2000's | 18 (39.13) | 29.6817 |
| 2010's | 16 (34.78) | 24.3611 |
| 2020's | 2 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, R | 1 |
| Shallis, RM | 1 |
| Stempel, JM | 1 |
| Huntington, SF | 1 |
| Zeidan, AM | 1 |
| Gore, SD | 1 |
| Ma, X | 1 |
| Podoltsev, NA | 1 |
| Pan, DQ | 1 |
| Zhao, WS | 1 |
| Yin, CX | 1 |
| He, H | 1 |
| Lin, R | 1 |
| Zhao, K | 1 |
| Ye, JY | 1 |
| Liu, QF | 1 |
| Dai, M | 1 |
| Chang, L | 1 |
| Duan, MH | 1 |
| Park, S | 1 |
| Hamel, JF | 1 |
| Toma, A | 1 |
| Kelaidi, C | 1 |
| Thépot, S | 1 |
| Campelo, MD | 1 |
| Santini, V | 1 |
| Sekeres, MA | 1 |
| Balleari, E | 1 |
| Kaivers, J | 1 |
| Sapena, R | 1 |
| Götze, K | 1 |
| Müller-Thomas, C | 1 |
| Beyne-Rauzy, O | 1 |
| Stamatoullas, A | 1 |
| Kotsianidis, I | 1 |
| Komrokji, R | 1 |
| Steensma, DP | 1 |
| Fensterl, J | 1 |
| Roboz, GJ | 1 |
| Bernal, T | 1 |
| Ramos, F | 1 |
| Calabuig, M | 1 |
| Guerci-Bresler, A | 1 |
| Bordessoule, D | 2 |
| Cony-Makhoul, P | 1 |
| Cheze, S | 1 |
| Wattel, E | 2 |
| Rose, C | 1 |
| Vey, N | 1 |
| Gioia, D | 1 |
| Ferrero, D | 1 |
| Gaidano, G | 1 |
| Cametti, G | 1 |
| Pane, F | 1 |
| Sanna, A | 1 |
| Germing, U | 1 |
| Sanz, GF | 1 |
| Dreyfus, F | 1 |
| Fenaux, P | 4 |
| Janakiram, M | 1 |
| Verma, A | 1 |
| Wang, Y | 1 |
| Budhathoki, A | 1 |
| Suarez Londono, J | 1 |
| Murakhovskaya, I | 1 |
| Braunschweig, I | 1 |
| Minniti, CP | 1 |
| Huemer, F | 1 |
| Weiss, L | 1 |
| Faber, V | 1 |
| Neureiter, D | 1 |
| Egle, A | 1 |
| Geissler, K | 1 |
| Voskova, D | 1 |
| Zebisch, A | 1 |
| Burgstaller, S | 1 |
| Pichler, A | 1 |
| Stauder, R | 1 |
| Sperr, W | 1 |
| Lang, A | 1 |
| Pfeilstöcker, M | 1 |
| Machherndl-Spandl, S | 1 |
| Stampfl, M | 1 |
| Greil, R | 1 |
| Pleyer, L | 1 |
| Wang, HY | 1 |
| Dell'Aquila, ML | 1 |
| Dvanajscak, Z | 1 |
| Bejar, R | 1 |
| Broome, HE | 1 |
| Hsi, E | 1 |
| Murray, SS | 1 |
| Thorson, JA | 1 |
| Ghosh, K | 2 |
| Bain, BJ | 1 |
| Garnett, C | 1 |
| Deplano, S | 1 |
| Naresh, K | 1 |
| Kanfer, E | 1 |
| Shimizu, T | 1 |
| Mori, T | 1 |
| Karigane, D | 1 |
| Kikuchi, T | 1 |
| Koda, Y | 1 |
| Toyama, T | 1 |
| Nakajima, H | 1 |
| Okamoto, S | 1 |
| Itzykson, R | 1 |
| Itzkson, R | 1 |
| Solary, E | 1 |
| Gotlib, J | 1 |
| Crittenden, SC | 1 |
| Gilbert, JE | 1 |
| Callen, JP | 2 |
| Willemze, R | 1 |
| Suciu, S | 1 |
| Muus, P | 1 |
| Halkes, CJ | 1 |
| Meloni, G | 2 |
| Meert, L | 1 |
| Karrasch, M | 1 |
| Rapion, J | 1 |
| Vignetti, M | 1 |
| Amadori, S | 1 |
| de Witte, T | 1 |
| Marie, JP | 1 |
| Björkholm, M | 1 |
| Hultcrantz, M | 1 |
| Derolf, ÅR | 1 |
| Aumont, C | 1 |
| Driss, F | 1 |
| Lazure, T | 1 |
| Picard, V | 1 |
| Creidy, R | 1 |
| De Botton, S | 1 |
| Saada, V | 1 |
| Lambotte, O | 1 |
| Bilhou-Nabera, C | 1 |
| Tertian, G | 1 |
| Michot, JM | 1 |
| Sunami, Y | 1 |
| Gotoh, A | 1 |
| Watanabe, N | 1 |
| Edahiro, Y | 1 |
| Hamano, Y | 1 |
| Harada, H | 1 |
| Komatsu, N | 1 |
| Nand, S | 1 |
| Godwin, J | 1 |
| Smith, S | 1 |
| Barton, K | 1 |
| Michaelis, L | 1 |
| Alkan, S | 1 |
| Veerappan, R | 1 |
| Rychlik, K | 1 |
| Germano, E | 1 |
| Stiff, P | 1 |
| Cook-Norris, RH | 1 |
| Mansfield, AS | 1 |
| Michaels, JD | 1 |
| Davis, MD | 1 |
| Kalajian, AH | 1 |
| Cely, SJ | 1 |
| Malone, JC | 1 |
| Burruss, JB | 1 |
| Petti, MC | 1 |
| Tafuri, A | 1 |
| Latagliata, R | 1 |
| Aloe Spiriti, MA | 1 |
| Montefusco, E | 1 |
| Mancini, M | 1 |
| Petrucci, MT | 1 |
| Spadea, A | 1 |
| Redi, R | 1 |
| Alimena, G | 1 |
| Mandelli, F | 1 |
| Spell, DW | 1 |
| Nielsen, I | 1 |
| Hasselbalch, HC | 1 |
| Lengfelder, E | 1 |
| Berger, U | 1 |
| Reiter, A | 1 |
| Hochhaus, A | 1 |
| Hehlmann, R | 1 |
| Fruchtman, SM | 1 |
| Winer, ES | 1 |
| Miller, KB | 1 |
| Chan, GW | 1 |
| Thiele, J | 1 |
| Kvasnicka, HM | 1 |
| Ollig, S | 1 |
| Schmitt-Gräff, A | 2 |
| Daskalakis, M | 1 |
| Mauritzson, N | 1 |
| Johansson, B | 1 |
| Bouabdallah, K | 1 |
| Onida, F | 1 |
| Kunzmann, R | 1 |
| Müller-Berndorff, H | 1 |
| Lübbert, M | 1 |
| Kiladjian, JJ | 1 |
| Rain, JD | 2 |
| Bernard, JF | 1 |
| Briere, J | 1 |
| Chomienne, C | 1 |
| Gologan, R | 1 |
| Stoia, R | 1 |
| Radulescu, I | 1 |
| Georgescu, D | 1 |
| Ostroveanu, D | 1 |
| Burnett, AK | 1 |
| Milligan, D | 1 |
| Prentice, AG | 1 |
| Goldstone, AH | 1 |
| McMullin, MF | 1 |
| Hills, RK | 1 |
| Wheatley, K | 1 |
| Ostro, D | 1 |
| Cheung, K | 1 |
| Kamel-Reid, S | 1 |
| Lipton, JH | 1 |
| Najean, Y | 1 |
| Toubert, ME | 1 |
| Pellier, I | 1 |
| Le Moine, PJ | 1 |
| Rialland, X | 1 |
| François, S | 1 |
| Baranger, L | 1 |
| Blanchet, O | 1 |
| Larget-Piet, L | 1 |
| Ifrah, N | 1 |
| Pulik, M | 1 |
| Lionnet, F | 1 |
| Genet, P | 1 |
| Petitdidier, C | 1 |
| Jary, L | 1 |
| Touahri, T | 1 |
| Jacob, A | 1 |
| Griffiths, M | 1 |
| Larkins, S | 1 |
| Holmes, J | 1 |
| Sterkers, Y | 1 |
| Preudhomme, C | 1 |
| Laï, JL | 1 |
| Demory, JL | 1 |
| Caulier, MT | 1 |
| Bauters, F | 1 |
| Tefferi, A | 1 |
| Randi, ML | 2 |
| Fabris, F | 2 |
| Girolami, A | 2 |
| Horikoshi, M | 1 |
| Machida, U | 1 |
| Itikawa, M | 1 |
| Seo, S | 1 |
| Masuda, S | 1 |
| Kurokawa, M | 1 |
| Ogawa, S | 1 |
| Sunaga, S | 1 |
| Honda, H | 1 |
| Aoki, K | 1 |
| Chiba, S | 1 |
| Mitani, K | 1 |
| Hirai, H | 1 |
| Yazaki, Y | 1 |
| Finazzi, G | 2 |
| Ruggeri, M | 1 |
| Rodeghiero, F | 1 |
| Barbui, T | 2 |
| Flamm, MJ | 1 |
| Murty, VV | 1 |
| Rao, PH | 1 |
| Nichols, GL | 1 |
| Advani, SH | 2 |
| Venugopal, P | 1 |
| Charak, BS | 1 |
| Das Gupta, A | 2 |
| Mazumdar, AT | 1 |
| Gopal, R | 2 |
| Nair, CN | 2 |
| Saikia, TK | 2 |
| Nadkarni, KS | 1 |
| Kurkure, PA | 2 |
| van den Anker-Lugtenburg, PJ | 1 |
| Sizoo, W | 1 |
| Giri, NK | 1 |
| Dole, MG | 1 |
| Pai, SK | 1 |
| Pai, VR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Integrated European Platform to Conduct Translational Studies in Myelodysplastic Syndromes Based on the EuroBloodNet Infrastructure[NCT04174547] | 8,670 participants (Anticipated) | Observational | 2019-09-30 | Recruiting | |||
| Austrian Myeloid Registry[NCT04438889] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2020-07-13 | Recruiting | |||
| A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over[NCT00005823] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1998-12-31 | Completed | ||
| A Phase I-II, Multicentre, Open Label Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine, Plus Venetoclax and Quizartinib in Newly Diagnosed Acute Myeloid Leukemia Patients Aged Equal or More Than[NCT04687761] | Phase 1/Phase 2 | 84 participants (Anticipated) | Interventional | 2020-11-04 | Recruiting | ||
| The Clinical Research About the Therapeutic Effect and Safety of 10 Days Regimen With Single-agent of Decitabine for Elderly AML Patients[NCT01633099] | Phase 3 | 46 participants (Anticipated) | Interventional | 2012-05-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for hydroxyurea and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
[Hydroxyurea (hydroxycarbamide)-induced hepatic dysfunction confirmed by drug-induced lymphocyte stimulation test].
Topics: Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Fatal Outcome; Humans; Hydroxyurea; I | 2014 |
Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?
Topics: Allografts; Antineoplastic Agents; Blast Crisis; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, | 2013 |
World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Bone Marrow Examination; Clone Cells; Disease Manage | 2014 |
Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Disease Progression; Humans; Hydroxyurea; Ja | 2014 |
Treatment paradigms in the management of myeloproliferative disorders.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Chlorambucil; Hydroxyurea; Interferon-alpha; Leukemia, | 2004 |
Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Topics: Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Interfero | 2006 |
Myelodysplastic syndrome with t(5;12)(q31;p12-p13) and eosinophilia: a pediatric case with review of literature.
Topics: Adult; Child; Chromosome Mapping; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 5; Eosinophi | 1996 |
Efficacy and safety of hydroxyurea in patients with essential thrombocythemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Cell Transformation, Neoplastic; Cohort Studies; Female; Fol | 2001 |
5 trials available for hydroxyurea and Dysmyelopoietic Syndromes
33 other studies available for hydroxyurea and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea.
Topics: Aged; Aged, 80 and over; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Medicare; Myelodysplastic Sy | 2023 |
Topics: Adult; Aged; Anemia; Bone Marrow; Female; Hemoglobins; Humans; Hydroxyurea; Male; Middle Aged; Myelo | 2022 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; | 2017 |
Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease.
Topics: Acute Disease; Adult; Anemia, Sickle Cell; Antineoplastic Agents; Cell Transformation, Neoplastic; F | 2018 |
Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Female; Humans; Hydroxyurea; Leukemia, Myelomonocytic, | 2018 |
JAK2 double minutes with resultant simultaneous amplification of JAK2 and CD274 in a therapy-related myelodysplastic syndrome evolving into an acute myeloid leukaemia.
Topics: Aged, 80 and over; B7-H1 Antigen; Gene Amplification; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, | 2019 |
Iron chelators or therapeutic modulators of iron overload: Are we anywhere near ideal one?
Topics: Animals; beta-Thalassemia; Chelating Agents; Deferiprone; Deferoxamine; Humans; Hydroxyurea; Iron Ov | 2018 |
Dysplasia of all granulocyte lineages in myelodysplastic evolution of essential thrombocythemia.
Topics: Aged; Amino Acid Substitution; Antineoplastic Agents; Aspirin; Bone Marrow; Cell Lineage; Cell Trans | 2013 |
Hydroxyurea-induced leg ulceration in a patient with a homozygous MTHFR polymorphism misdiagnosed as pyoderma gangrenosum.
Topics: Aged; Antineoplastic Agents; Diagnostic Errors; Female; Humans; Hydroxyurea; Leg Ulcer; Methylenetet | 2014 |
Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia.
Topics: Anemia, Sickle Cell; Antineoplastic Agents; Antisickling Agents; Chromosome Aberrations; Chromosomes | 2015 |
[Chronic Myelomonocytic Leukemia with Myelofibrosis Resulting in Sudden Massive Pleural Effusion during Cytoreductive Therapy with Hydroxycarbamide].
Topics: Antineoplastic Agents; Cytoreduction Surgical Procedures; Drainage; Humans; Hydroxyurea; Leukemia, M | 2016 |
Hydroxycarbamide-induced dermopathy.
Topics: Antisickling Agents; Female; Humans; Hydroxyurea; Middle Aged; Myelodysplastic Syndromes; Pruritus | 2010 |
Hydroxyurea-associated dermatomyositis-like eruption demonstrating abnormal epidermal p53 expression: a potential premalignant manifestation of chronic hydroxyurea and UV radiation exposure.
Topics: Aged, 80 and over; Dermatomyositis; Diagnosis, Differential; DNA, Neoplasm; Drug Eruptions; Epidermi | 2010 |
High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias.
Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Cytogenetic Analysis; Dose-Response Relat | 2003 |
Long-term use of hydroxyurea for sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Leukemia; Myelodysplastic Syndromes | 2003 |
Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Topics: Acute Disease; Alkylating Agents; Busulfan; Chronic Disease; Drug Therapy, Combination; Female; Huma | 2003 |
[Chronic myeloproliferative diseases. Diagnosis and therapy].
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Transplantation; Chronic Disease; Diagno | 2003 |
GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2005 |
Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea.
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Humans; Hydroxyurea; Immunohistochemistry; Me | 2005 |
Trisomy 19 as the sole chromosomal abnormality in proliferative chronic myelomonocytic leukemia.
Topics: Aged; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 19; Cytarabine; Cytogenetic Anal | 2006 |
Chronic myelomonocytic leukemia with overlap dysplastic/proliferative presentation.
Topics: Aged; Antineoplastic Agents; Fatal Outcome; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chro | 2007 |
Chromosomal abnormalities in chronic myeloid leukemia: evidence of a hierarchy in imatinib treated cells.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Chromosome Aberrations; Cytogenetics; H | 2007 |
Acute myeloid leukemia evolving from polycythemia vera in a patient treated with hydroxyurea.
Topics: Adult; Bone Marrow; Disease Progression; Fatal Outcome; Humans; Hydroxyurea; Leukemia, Monocytic, Ac | 1996 |
t(3;21) following peripheral blood stem cell transplantation in chronic phase chronic myeloid leukaemia.
Topics: Adult; Antineoplastic Agents; Chromosome Banding; Chromosomes, Human, Pair 21; Chromosomes, Human, P | 1997 |
Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.
Topics: Adult; Aged; Antisickling Agents; Chromosomes, Human, Pair 17; Female; Gene Deletion; Humans; Hydrox | 1998 |
Is hydroxyurea leukemogenic in essential thrombocythemia?
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Bone Marrow; Busulfan; Chromosome Aberrations; Chr | 1998 |
Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Busulfan; Female; Follow-Up Studies; Humans; | 1999 |
[Essential thrombocythemia in transformation from myelodysplastic syndrome to acute myeloid leukemia with inv(3) after treatment for gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair | 2000 |
Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Busulfan; Fatal Outcome; Female; Humans; Hydro | 2000 |
Coexistence of independent myelodysplastic and Philadelphia chromosome positive clones in a patient treated with hydroxyurea.
Topics: Aged; Antineoplastic Agents; Blast Crisis; Cell Differentiation; Chronic Disease; Female; Humans; Hy | 2002 |
Effect of hydroxyurea on foetal haemoglobin in myeloproliferative & myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Child; Female; Fetal Hemoglobin; Humans; Hydroxyurea; Male; Middle Aged; My | 1990 |
Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with hydroxyurea.
Topics: Acute Disease; Female; Humans; Hydroxyurea; Leukemia; Middle Aged; Myelodysplastic Syndromes; Thromb | 1990 |
Limitations of the therapeutic regimens for myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; | 1989 |